-transparent.png){kind=logo}
The fate of silvex [2-(2,4,5-trichlorophenoxy)propionic acid] was defined in seven men and in one woman following oral administration of 1 mg/kg. No adverse effects were observed. Samples of blood plasma, urine, and feces were collected at designated time intervals through 168 hr. Plasma samples were analyzed for silvex only, while samples of urine and feces were analyzed for silvex, silvex conjugate(s), 2,4,5-trichlorophenol, and 2,4,5-trichlorophenol conjugate(s). Apparent first-order kinetics described the biphasic clearance of silvex from plasma and excretion in urine. The half-life values for clearance of silvex from plasma were 4.0 +/- 1.9 and 16.5 +/- 7.3 hr for the initial and terminal phases, respectively. Peak plasma levels of silvex occurred within 2-4 hr after dosage. Within 24 hr after administration, 65% of the administered dose had been excreted in urine. Silvex was excreted in urine as silvex and silvex conjugate(s). The half-life values for excretion of silvex per se in urine were 5.0 +/- 1.8 and 25.9 +/- 6.3 hr for the two phases, respectively. Small amounts (3.2% or less) of silvex and/or silvex conjugate(s) were eliminated in feces. Recovery of silvex and its conjugate(s) in urine and feces through 168 hr ranged from 66.6 to 95.1% of the administered dose, with a mean value and standard deviation of 80.3 +/- 10.5%. In humans, silvex is readily absorbed after ingestion and subsequently readily excreted, predominantly via the urine.
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
February 1999,
Psychopharmacology,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
January 1977,
Journal of toxicology and environmental health,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
January 1974,
Journal of agricultural and food chemistry,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
January 1994,
Drug metabolism and disposition: the biological fate of chemicals,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
August 1977,
Toxicology,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
November 1973,
Toxicology and applied pharmacology,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
April 1991,
American journal of hypertension,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
January 1984,
Medical biology,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
January 1983,
Biopharmaceutics & drug disposition,
M W Sauerhoff, and
M B Chenoweth, and
R , Karbowski, and
W H Braun, and
J C Ramsey, and
P J Gehring, and
G E Blau
April 2014,
Xenobiotica; the fate of foreign compounds in biological systems,
